Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB571 in advanced non-small cell lung cancer
NCT07230405Phase 2Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Bispecific Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of SKB571 in non-small cell lung cancer (NSCLC), sponsored by Kelun-Biotech. Primary endpoints: Adverse Events up to 24 months and Objective Response Rate up to 24 months. Started Jan 2026; status: recruiting.
02
Drugs
SKB571
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07230405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230405.